Advice
Following a resubmission
Anagrelide (Xagrid) is accepted for use within NHS Scotland for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
Anagrelide reduces platelet counts in patients with essential thrombocythaemia who were intolerant of another cytoreductive therapy or whose platelet count could not be controlled by it.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- Anagrelide 0.5mg capsule (Xagrid®)
- SMC ID:
- 163/05
- Indication:
- Reduction of elevated platelet counts in 'at risk' patients with essential thrombocythaemia
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 10 October 2005